Appendix 4C - Quarterly - 30 September 2022
Filed with ASX · · 9 pages · English
Second engineering run of PAT-DX1 successfully passes specification testing providing material for final GLP toxicology studies to support Phase-1 clinical trial in 2H CY2023 Preclinical studies demonstrate PAT-DX1 improves effectiveness of radiation and survival in animal model of high grade glioma – a highly aggressive primary brain cancer Olivia Newton-John Cancer Research Institute award
Story so far
Earlier from Patrys
- PAT DX3 Crosses Blood Brain Barrier in Healthy Animals
- Appendix 4E and 2022 Annual Report
- PAT-DX1 From Engineering Run Meets all Specification Tests
- New Research Grant For Deoxymabs in Metastatic Breast Cancer
- PAT-DX1/Radiation Combination Improves Brain Cancer Survival
Later from Patrys
- Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
- Response to ASX Price Query
- Appendix 4C - Quarterly - 31 December 2022
- Appendix 4D - Half Year Accounts - 31 December 2022
- New PAT-DX3 data demonstrates synthetic lethality
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys